Myriad Genetics Inc: (NASD: MYGN)

$25.88

-0.56 (-2.12%)

Volume 2,812,338

Jun 19 04:00 PM ET

Zacks Rank: 1-Strong Buy

#1
 
 
 
 

Zacks Commentary

Get Zacks Commentary for:

Zacks Commentary For MYGN

Jun 19, 2013 Zacks Blog: Merge iConnect Solutions Wins Client

Jun 19, 2013 Zacks Blog: Iconix Brand Group, Ralph Lauren, DaVita HealthCare Partners, Myriad Genetics and Biogen Idec highlighted as Zacks Bull and Bear of the Day

Jun 19, 2013 Zacks Blog: MDT Expands Spine-Line in Europe

Jun 18, 2013 Zacks Blog: DaVita and Myriad Join Forces

Jun 18, 2013 Zacks Blog: The Zacks Analyst Blog Highlights: Myriad Genetics, Anika Therapeutics, Biogen Idec , Alexion Pharmaceuticals and Cabot Oil & Gas

Jun 17, 2013 Zacks Blog: German Court Rules in Favor of MDT

Jun 17, 2013 Zacks Blog: Myriad: End to Legal Battle over Patents

Jun 14, 2013 Zacks Blog: LIFE Continues Korean Expansion

Jun 14, 2013 Zacks Blog: Company News for June 14, 2013

Jun 11, 2013 Zacks Blog: SGEN Starts Adcetris Phase I/II Study

Jun 11, 2013 Zacks Blog: Zimmer Stays at Neutral

Jun 11, 2013 Zacks Blog: Life Expands Portfolio

Quick Links

Services

My Account

Resources

Client Support

Follow Us

Facebook

Twitter

Linkedin

RSS

You Tube

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.

Copyright 2013 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.

Visit performance for information about the performance numbers displayed above.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.